Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]

NCT06962800 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT06962800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT]
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Recruiting
Start date
May 22, 2025
Completion date
January 17, 2031
Enrollment
180 (estimated)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy